Heerspink HJL - Search Results

1

Studying Telmisartan Plasma Exposure, Kidney Distribution, Receptor Occupancy, and Response in Patients With Type 2 Diabetes Using [¹¹ C]Telmisartan.

van der Hoek S, Mulder DJ, Willemsen ATM, Visser T, Heeres A, Slart RHJA, Elsinga PH, Heerspink HJL, Stevens J. van der Hoek S, et al. Among authors: heerspink hjl. Clin Pharmacol Ther. 2022 Dec;112(6):1264-1270. doi: 10.1002/cpt.2744. Epub 2022 Sep 30. Clin Pharmacol Ther. 2022. PMID: 36070078 Free PMC article.

2

Arterial Stiffness Is Positively Associated With 18F-fluorodeoxyglucose Positron Emission Tomography-Assessed Subclinical Vascular Inflammation in People With Early Type 2 Diabetes.

de Boer SA, Hovinga-de Boer MC, Heerspink HJ, Lefrandt JD, van Roon AM, Lutgers HL, Glaudemans AW, Kamphuisen PW, Slart RH, Mulder DJ. de Boer SA, et al. Diabetes Care. 2016 Aug;39(8):1440-7. doi: 10.2337/dc16-0327. Epub 2016 Jun 8. Diabetes Care. 2016. PMID: 27281773

3

Effect of Linagliptin on Arterial ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography Uptake: A Randomized Controlled Trial (RELEASE).

de Boer SA, Heerspink HJ, Lefrandt JD, Hovinga-de Boer MC, van Roon AM, Juárez Orozco LE, Glaudemans AW, Kamphuisen PW, Slart RH, Mulder DJ. de Boer SA, et al. J Am Coll Cardiol. 2017 Feb 28;69(8):1097-1098. doi: 10.1016/j.jacc.2016.12.018. J Am Coll Cardiol. 2017. PMID: 28231936 Free article. No abstract available.

4

Effect of linagliptin on pulse wave velocity in early type 2 diabetes: A randomized, double-blind, controlled 26-week trial (RELEASE).

de Boer SA, Heerspink HJL, Juárez Orozco LE, van Roon AM, Kamphuisen PW, Smit AJ, Slart RHJA, Lefrandt JD, Mulder DJ. de Boer SA, et al. Among authors: heerspink hjl. Diabetes Obes Metab. 2017 Aug;19(8):1147-1154. doi: 10.1111/dom.12925. Epub 2017 Apr 10. Diabetes Obes Metab. 2017. PMID: 28244635 Clinical Trial.

5

Determining the optimal dose of atrasentan by evaluating the exposure-response relationships of albuminuria and bodyweight.

Koomen JV, Stevens J, Mostafa NM, Parving HH, de Zeeuw D, Heerspink HJL. Koomen JV, et al. Among authors: heerspink hjl. Diabetes Obes Metab. 2018 Aug;20(8):2019-2022. doi: 10.1111/dom.13312. Epub 2018 May 1. Diabetes Obes Metab. 2018. PMID: 29603851 Free PMC article. Clinical Trial.

6

Association between individual cholesterol and proteinuria response and exposure to atorvastatin or rosuvastatin.

Kroonen MYAM, Stevens J, de Zeeuw D, Heerspink HJL. Kroonen MYAM, et al. Among authors: heerspink hjl. Diabetes Obes Metab. 2019 Dec;21(12):2635-2642. doi: 10.1111/dom.13849. Epub 2019 Sep 30. Diabetes Obes Metab. 2019. PMID: 31414562 Free PMC article. Clinical Trial.

7

Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial.

Koomen JV, Heerspink HJL, Schrieks IC, Schwartz GG, Lincoff AM, Nicholls SJ, Svensson A, Wedel H, Weichert A, Grobbee DE, Stevens J. Koomen JV, et al. Among authors: heerspink hjl. Diabetes Obes Metab. 2020 Jan;22(1):30-38. doi: 10.1111/dom.13862. Epub 2019 Oct 1. Diabetes Obes Metab. 2020. PMID: 31468659 Free PMC article. Clinical Trial.

8

Exposure-response relationships for the sodium-glucose co-transporter-2 inhibitor dapagliflozin with regard to renal risk markers.

Kroonen MYAM, Koomen JV, Petrykiv SI, Laverman GD, Heerspink HJL, Stevens J. Kroonen MYAM, et al. Among authors: heerspink hjl. Diabetes Obes Metab. 2020 Jun;22(6):916-921. doi: 10.1111/dom.13976. Epub 2020 Feb 17. Diabetes Obes Metab. 2020. PMID: 31984620 Free PMC article. Clinical Trial.

9

Angiogenic T cells are decreased in people with type 2 diabetes mellitus and recruited by the dipeptidyl peptidase-4 inhibitor Linagliptin: A subanalysis from a randomized, placebo-controlled trial (RELEASE study).

de Boer SA, Reijrink M, Abdulahad WH, Hoekstra ES, Slart RHJA, Heerspink HJL, Westra J, Mulder DJ. de Boer SA, et al. Among authors: heerspink hjl. Diabetes Obes Metab. 2020 Jul;22(7):1220-1225. doi: 10.1111/dom.14024. Epub 2020 Mar 27. Diabetes Obes Metab. 2020. PMID: 32166899 Free PMC article. Clinical Trial.

10

Exposure-response relationships of dapagliflozin on cardiorenal risk markers and adverse events: A pooled analysis of 13 phase II/III trials.

Koomen JV, Stevens J, Heerspink HJL. Koomen JV, et al. Among authors: heerspink hjl. Br J Clin Pharmacol. 2020 Nov;86(11):2192-2203. doi: 10.1111/bcp.14318. Epub 2020 May 10. Br J Clin Pharmacol. 2020. PMID: 32311110 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

433 results

Search Page